%0 Journal Article
%T Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study
%A Caitlyn T Solem
%A Christian Heidbreder
%A Della Varghese
%A James A Graham
%A Maurizio Fava
%A Namita Joshi
%A Rahul Dhanda
%A Susan M Learned
%A Vijay R Nadipelli
%J Archive of "Patient preference and adherence".
%D 2019
%R 10.2147/PPA.S202173
%X RBP-7000 (PERSERIS£¿) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this study was to describe the long-term impact of RBP-7000 on health-related quality of life (HRQoL), subjective well-being, treatment satisfaction and medication preference in patients with schizophrenia
%K antipsychotics
%K quality of life
%K medication satisfaction
%K medication preference
%K clinical trial
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612993/